非酒精性脂肪性肝病患者血清Maresin-1、网膜蛋白-1和微小RNA-125b水平变化及其与病情严重程度的关系研究*

doi:10.3969/j.issn.1672-5069.2025.04.014

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)患者血清Maresin-1、脂肪因子网膜蛋白-1(omentin-1)和微小RNA-125b(miR-125b)水平变化及其与病情严重程度的关系。方法 2024 年1月～2024年6月我院诊治的NAFLD患者103例和健康体检者67例,采用ELISA法检测血清Maresin-1和Omentin-1水平,采用RT-PCR法检测血清miR-125b水平。经肝活检检查,根据NAFLD活动度积分(NAS)诊断非酒精性脂肪性肝炎(NASH)和肝纤维化。应用受试者工作特征曲线(ROC)评估血清Maresin-1、Omentin-1和miR-125b水平诊断肝纤维化的效能。结果在103例NAFLD患者中,肝组织学检查诊断肝硬化15例、NASH者57例(其中伴肝纤维化36例,早期肝纤维化21例)和单纯性脂肪肝31例;肝硬化组血清Maresin-1、Omentin-1和miR-125b水平分别为(43.7±5.2)pg/mL、(1.2±0.3)ng/mL和(0.6±0.1),显著低于NASH组【分别为(59.3±5.8)pg/mL、(2.4±0.5)ng/mL和(1.0±0.3),P＜0.05】或单纯性脂肪肝组【分别为(67.2±6.6)pg/mL、(3.2±0.7)ng/mL和(1.6±0.4),P＜0.05】或健康体检组【分别为(78.5±7.3)pg/mL、(4.3±0.9)ng/mL和(2.3±0.5),P＜0.05】;伴肝纤维化NASH组血清Maresin-1、Omentin-1和miR-125b水平分别为(56.9±5.6)pg/mL、(2.1±0.6)ng/mL和(0.8±0.2),显著低于早期NASH组【分别为(63.4±5.3)pg/mL、(2.9±0.8)ng/mL和(1.3±0.3),P＜0.05】; ROC曲线分析显示,血清Maresin-1、Omentin-1和miR-125b水平联合诊断伴肝纤维化NASH的曲线下面积(ACU)为0.912,其敏感性为97.2%,特异性为71.4%,显著优于三项指标单独诊断(P＜0.05)。结论 NAFLD患者血清Maresin-1、Omentin-1和miR-125b水平降低,显著降低的指标水平可能预示伴有肝纤维化,需进一步采取措施以明确诊断和干预。

关键词: 非酒精性脂肪性肝病, 非酒精性脂肪性肝炎, Maresin-1, 网膜蛋白-1, 微小RNA-125b, 诊断

Abstract: Objective The aim of this study was to explore changes of serum maresin-1, omentin-1 and microRNA-125b (miR-125b) levels, and their correlation to liver inflammation and liver fibrosis (LF) in patients with non-alcoholic fatty liver disease (NAFLD). Methods A total of 103 patients with NAFLD and 67 healthy individuals were enrolled in our hospital between January and June 2024, serum maresin-1 and omentin-1 levels were detected by ELISA, and miR-125b level was assayed by RT-PCR. All patients with NAFLD underwent liver biopsy, and non-alcoholic steatohepatitis (NASH) and LF were diagnosed based on NAFLD activity scores (NAS). The diagnostic efficacy of serum maresin-1, omentin-1 and miR-125b levels for LF was evaluated by receiver operating characteristic (ROC) curves. Results Of 103 patients with NAFLD, liver histo-pathological examination proved liver cirrhosis (LC) in 15 cases, NASH in 57 cases (including significantLF in 36 cases and mild LF in 21 cases), and simple fatty liver (SFL) in 31 cases; serum maresin-1, omentin-1 and miR-125b levels in cirrhosis group were (43.7±5.2) pg/mL, (1.2±0.3) ng/mL and (0.6±0.1), all significantly lower than [(59.3±5.8) pg/mL, (2.4±0.5) ng/mL and (1.0±0.3), P<0.05]in NASH group, or [(67.2±6.6) pg/mL, (3.2±0.7) ng/mL and (1.6±0.4), P<0.05] in SFL group or [(78.5±7.3) pg/mL, (4.3±0.9) ng/mL and (2.3±0.5) ng/ml, respectively, P<0.05] in control group; serum maresin-1, omentin-1 and miR-125b levels in NASH patients with significant LF were (56.9±5.6) pg/mL, (2.1±0.6) ng/mL and (0.8±0.2), all significantly lower than [(63.4±5.3) pg/mL, (2.9±0.8) ng/mL and (1.3±0.3), respectively, P<0.05] in those with mild LF; ROC analysis showed that area under the curve (ACU) of serum maresin-1, omentin-1 and miR-125b level combination in the diagnosis of NASH with significant LF was 0.912, with sensitivity of 97.2% and specificity of 71.4%, much superior to any parameter did alone (P<0.05). Conclusion Serum maresin-1, omentin-1 and miR-125b levels in patients with NAFLD reduce, and very low of them might indicate the existence of NASH and LF, which warrants further interventions.

Key words: Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Maresin-1, Omentin-1, MicroRNA-125b, Diagnosis

倪沈珏, 王鹏飞, 黄燕华, 曹利华. 非酒精性脂肪性肝病患者血清Maresin-1、网膜蛋白-1和微小RNA-125b水平变化及其与病情严重程度的关系研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 533-536.

Ni Shenjue, Wang Pengfei, Huang Yanhua, et al. Changes of serum maresin-1, omentin-1 and microRNA-125b, and their correlation to liver inflammation and fibrosis in patients with non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(4): 533-536.

参考文献

[1] Heo JH, Lee MY, Kim SH,et al. Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study. Hepatobiliary Surg Nutr, 2024, 13(5):801-813.
[2] Xue B, Wang Z, Li J. Systemic immune-inflammation index as a prognostic marker for chronic Hepatitis B with non-alcoholic fatty liver disease. J Infect Dev Ctries, 2025, 19(2):315-324.
[3] Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res, 2024, 55(6):103043.
[4] Malnick SDH, Zamir D. From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology. World J Hepatol, 2024, 16(6):863-866.
[5] 刘岗,张浩,胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨. 实用肝脏病杂志,2023,26(2):197-201.
[6] Chuah KH, Chan WK. Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future. Clin Mol Hepatol, 2023, 29(2):401-403.
[7] Rodriguez MJ, Sabaj M, Tolosa G, et al. Maresin-1prevents liver fibrosis by targeting Nrf2 and NF-κB, reducing oxidative stress and inflammation. Cells, 2021, 10(12):3406.
[8] Peschel G, Weigand K, Grimm J, et al. Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C. World J Hepatol, 2023, 15(12):1315-1324.
[9] Li B, Xiao Q, Zhao H, et al. Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism. Acta Pharm Sin B, 2024, 14(9):3949-3963.
[10] El-Naidany SS, Zid E, Reda FM, et al. Clinicalsignificance of MiR-130b and MiR-125b as biomarkers in hepatocellular carcinoma. Asian Pac J Cancer Prev, 2022, 23(8):2687-2693.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018,21(2):177-186.
[12] Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol, 2023, 8(7):660-670.
[13] Li J, Ha A, Rui F, et al. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. Aliment Pharmacol Ther, 2022, 56(3):396-406.
[14] Dai JJ, Zhang YF, Zhang ZH. Global trends and hotspots of treatment for nonalcoholic fatty liver disease: a bibliometric and visualization analysis (2010-2023). World J Gastroenterol, 2023, 29(37):5339-5360.
[15] 童静,张珂瓈,李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨. 实用肝脏病杂志,2024,27(2):202-205.
[16] Tsujita Y, Sofue K, Ueshima E, et al. Clinicalapplication of quantitative MR imaging in nonalcoholic fatty liver disease. Magn Reson Med Sci, 2023, 22(4):435-445.
[17] Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J Hepatol, 2023, 78(1):45-56.
[18] Li T, Zeng H, Xian W, et al. Maresin 1 alleviates liver ischemia/reperfusion injury by reducing liver macrophage pyroptosis. J Transl Med, 2023, 21(1):472.
[19] Albayrak S, Aydin MA, Ugur K, et al. Subfatin, asprosin, alamandine and maresin-1 in cerebral ischemia, intracranial and subarachnoid hemorrhages. Eur Rev Med Pharmacol Sci, 2023, 27(10):4471-4480.
[20] Martinez-Fernandez L, Gonzalez-Muniesa P, Sainz N, et al. Maresin 1 regulates insulin signaling in human adipocytes as well as in adipose tissue and muscle of lean and obese mice. J Physiol Biochem, 2021, 77(1):167-173.
[21] Salvoza N, Giraudi P, Gazzin S, et al. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies. J Transl Med, 2023, 21(1):906.
[22] Huang Z, Luo L, Xiao Z, et al. Omentin-1 mitigates non-alcoholic fatty liver disease by preserving autophagy through AMPKα/mTOR signaling pathway. Sci Rep, 2024, 14(1):31464.
[23] Wei X, Zhao L, Ren R, et al. MiR-125b loss activated HIF1α/pAKT Loop, leading to transarterial chemoembolization resistance in hepatocellular carcinoma. Hepatology, 2021, 73(4):1381-1398.
[24] Zhang Q, Yu K, Cao Y, et al. miR-125b promotes the NF-κB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3. Life Sci, 2021, 270(1):119071.

非酒精性脂肪性肝病患者血清Maresin-1、网膜蛋白-1和微小RNA-125b水平变化及其与病情严重程度的关系研究^*

Changes of serum maresin-1, omentin-1 and microRNA-125b, and their correlation to liver inflammation and fibrosis in patients with non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	侯宇, 邹光旭, 赵英鹏. 代谢组学观点:揭示两种类型的脂肪性肝病^*[J]. 实用肝脏病杂志, 2025, 28(4): 485-488.
[2]	石丹丹, 艾碧琛, 马祺鑫, 李木兰, 张毅, 刘杰. 胆汁酸受体FXR对非酒精性脂肪性肝病糖脂代谢的作用研究进展^*[J]. 实用肝脏病杂志, 2025, 28(4): 489-492.
[3]	高倩, 陈璇, 周轶群, 杨欣, 康秀丽. 五脂胶囊联合复方甘草酸苷治疗非酒精性脂肪性肝炎患者疗效临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 529-532.
[4]	唐晓路, 邓玲, 王金春, 沈美龙. 水飞蓟素联合甘草酸二铵治疗非酒精性脂肪性肝炎患者疗效临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 537-540.
[5]	王超智, 王珊, 田婉婷. 依折麦布联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 541-544.
[6]	张淑玮, 张惠娟, 周杰. 罗格列酮联合二甲双胍治疗非酒精性脂肪性肝病合并T2DM患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 545-548.
[7]	王新田, 姚兰, 许珂, 韦颖. 非酒精性脂肪性肝病患者血清铁、铁蛋白轻链、不饱和铁结合力和转铁蛋白水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 549-552.
[8]	韩煜东, 张杰, 章文瑾, 何年安. 超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究[J]. 实用肝脏病杂志, 2025, 28(4): 553-556.
[9]	高晓婷, 高鑫, 刘艳莉, 康旺旺, 王海婷. 常规超声与超声造影评估肝硬化门静脉高压症患者TIPS术后支架功能价值分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 589-592.
[10]	李慧慧, 姚晓松, 肖征, 陈念. 肝细胞癌与肝内胆管癌超声表现和超声造影增强特点分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 597-600.
[11]	张聪, 张涛, 张骞. 超声造影诊断肝血管瘤及其预判肝动脉栓塞治疗的效果研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 601-604.
[12]	穆蕤, 李英, 刘萌雪, 杨卫健. 不典型肝脏局灶性结节性增生MRI征象表现研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 605-608.
[13]	温朝美, 史海洋. 超声超微血管成像技术联合静脉超声造影检查诊断肝局灶性病变价值研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 609-612.
[14]	陈春如, 齐浩龙, 鲁聪, 戴锴, 余佳. 昼夜节律在非酒精性脂肪性肝病发病过程中的作用研究进展^*[J]. 实用肝脏病杂志, 2025, 28(3): 321-325.
[15]	陆逸凡, 陈号, 怀家轩, 孙婧, 王高祥, 吴其标, 周希乔. 桥本氏甲状腺炎与非酒精性脂肪性肝病关系研究进展^*[J]. 实用肝脏病杂志, 2025, 28(3): 326-329.